18h
GlobalData on MSNRegeneron’s macular oedema therapy shows promise in Phase III trialIn the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.
Loss to follow-up higher among men who are Black or Hispanic, or those who must travel farther to care facilities.
The following is a summary of “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy,” published in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results